Enjoy complimentary customisation on priority with our Enterprise License!
The female infertility drugs market share is expected to increase by USD 538.69 million from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 4.71%.
This female infertility drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers female infertility drugs market segmentation by route of administration (parenteral, oral, and vaginal) and geography (North America, Europe, Asia, and ROW). The female infertility drugs market report also offers information on several market vendors, including AbbVie Inc., Aurobindo Pharma Ltd., Dr. Reddys Laboratories Ltd., Ferring B.V., Lupin Ltd., Merck KGaA, Mylan NV, Novartis AG, Sanofi SA, and Takeda Pharmaceutical Co. Ltd. among others.
Download the Free Report Sample to Unlock the Female Infertility Drugs Market Size for the Forecast Period and Other Important Statistics
The adverse effects and high cost of non-therapeutics are notably driving the female infertility drugs market growth, although factors such as the availability of alternative treatment options may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the female infertility drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Female Infertility Drugs Market Driver
The adverse effects and high cost of non-therapeutics will boost the popularity of female infertility drugs. Various ART procedures, including IVF, IUI, and ICSI are available as alternatives to medications for the treatment of female infertility. However, these non-therapeutics are associated with several adverse effects, such as ovarian hyperstimulation syndrome, multiple-gestation pregnancies, multiple-birth infants, premature labor, low birth weight, and risk of cesarean delivery. Moreover, ART procedures are highly expensive, which act as a challenge to patient adherence to these methods. These factors will increase the use of therapeutics for treating female infertility, consequently fueling the growth of the market during the forecast period.
Key Female Infertility Drugs Market Trend
The introduction of biosimilars will be one of the critical female infertility drugs market trends influencing the growth of the market. As biologics are highly expensive and are not affordable by everyone, market vendors are focusing on launching new and cost-effective biosimilars. For instance, Ovaleap, a biosimilar to GONAL-f (follitropin alfa) from Merck KGaA, was launched by Teva Pharmaceutical Industries Ltd. Another version of biosimilar to GONAL-f named BEMFOLA was approved in Australia. The introduction of these low-cost biosimilars will promote patient adherence and boost the demand for female infertility drugs.
Key Female Infertility Drugs Market Challenge
Various alternatives to medications, such as surgical procedures and ART, are available for the treatment of female fertility. Surgical treatments are helpful in correcting pelvic abnormalities such as uterine fibroids and pelvic adhesions. The most common surgical procedures are laparoscopy, hysteroscopy, and abdominal myomectomy (removal of uterine fibroids). The main type of ART is IVF, which involves extracting a woman's eggs, fertilizing them in the laboratory, and then transferring the resulting embryos into the woman's uterus through the cervix. The availability of such effective alternative options is expected to hamper the growth of the global female infertility drugs market during the forecast period.
This female infertility drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the female infertility drugs market encompasses successful business strategies deployed by the key vendors. The female infertility drugs market is fragmented and the vendors are deploying growth strategies such as distributing their products globally through their subsidiaries and other distribution channels to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The female infertility drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
For more insights on the market share of various regions Request for a FREE sample now!
35% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for female infertility drugs in North America. However, the market growth rate in this region will be slower than the growth of the market in Asia and Europe.
The growing prevalence of female infertility, adverse outcomes, and the high cost of non-therapeutic treatment will facilitate the female infertility drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
To gain further insights on the market contribution of various segments Request for a FREE sample
The female infertility drugs market share growth by the parenteral segment will be significant during the forecast period. Drugs approved in this segment are mainly peptide hormonal preparations that mimic the physiological effects of gonadotropins. These hormonal analogs are primarily used as fertility medication for ovarian hyperstimulation and reversal of ovulation. The parenteral route is more convenient for these peptide drugs, which are prone to degradation when administered through the oral route. Hence, these drugs exhibit high bioavailability when administered through the parenteral route.
This report provides an accurate prediction of the contribution of all the segments to the growth of the female infertility drugs market size and actionable market insights on post COVID-19 impact on each segment.
Female Infertility Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2020 |
Forecast period |
2021-2025 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.71% |
Market growth 2021-2025 |
$ 538.69 million |
Market structure |
Fragmented |
YoY growth (%) |
3.97 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 35% |
Key consumer countries |
US, Canada, Germany, China, and UK |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
AbbVie Inc., Aurobindo Pharma Ltd., Dr. Reddys Laboratories Ltd., Ferring B.V., Lupin Ltd., Merck KGaA, Mylan NV, Novartis AG, Sanofi SA, and Takeda Pharmaceutical Co. Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Route of administration
Customer landscape
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.